
|Videos|March 22, 2017
Scrutiny Continues to Grow Around the Cost of Specialty Drugs
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Ferric Maltol to Adolescents, Addressing a Critical Gap in Iron Deficiency Care
2
FDA Approves First Oral GLP-1 for Weight Management
3
Occupational Factors Can Increase Risk of Long COVID
4
Reading Between the Codes: How Seemingly Unrelated Conditions May Signal Earlier Multiple Myeloma
5




































































































































































































